The long term objective of this application is to develop methods that enable the rapid identification of the mechanistic type and frequency of antineoplastic drug resistant cells within populations of blast cells obtained from patients with acute nonlymphocytic leukemia (ANLL). The importance of such methodologies cannot be understated, since they will not only aid in the immediate selection of therapy, but will also give direction to future research in the design of new therapeutic approaches, aimed at overcoming those mechanisms of drug resistance identified. These studies will focus on the two most effective agents currently available for treatment of ANLL, daunorubicin (DNR) and 1-B-D-arabinofuranosylcytosine (ara-C). We will utilize state-of-the-art flow cytometric and cell sorting technology to enhance detection of drug resistant cells. Our preliminary studies reveal that our flow cytometer can accurately detect sub-populations as infrequent as 0.016% of the total population.
Our specific aims propose: A. to refine methods of flow cytometric evaluation of intracellular DNR and to investigate the relationship between intracellular DNR content or concentration as determined by flow cytometry and neoplastic cellular sensitivity to the drug; B. to establish optimal conditions of flow cytometric detection of ara-C incorporation into the DNA of single cells, utilizing a fluorescent antibody technique. To aid in achieving this end, we will attempt to develop a monoclonal antibody which recognizes ara-C incorporated into DNA. DNA synthesis during ara-C exposure will be quanitified in individual cells by utilizing the established flow cytometric method for measuring bromodeoxyuridine incorporation into DNA; C. to correlate the type and frequency of biological or biochemical alterations observed in blast cells obtained from patient with ANLL with clinical response of these patients to ara-C and DNR.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Maryland Baltimore
Schools of Medicine
United States
Zip Code
Doyle, L A; Yang, W; Rishi, A K et al. (1996) H19 gene overexpression in atypical multidrug-resistant cells associated with expression of a 95-kilodalton membrane glycoprotein. Cancer Res 56:2904-7
Wills, P; Hickey, R; Ross, D et al. (1996) A novel in vitro model system for studying the action of ara-C. Cancer Chemother Pharmacol 38:366-72
Lenehan, P F; Gutierrez, P L; Wagner, J L et al. (1995) Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells. Cancer Chemother Pharmacol 35:377-86
Ross, D D; Cuddy, D P (1995) Consequences of 2',2'-difluorodeoxycytidine (gemcitabine) on replicative DNA synthesis in intact HL-60 cells. Semin Oncol 22:26-34
Ross, D D; Wooten, P J; Tong, Y et al. (1994) Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL. Blood 83:1337-47
Ross, D D; Cuddy, D P (1994) Molecular effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells. Biochem Pharmacol 48:1619-30
Ross, D D; Wooten, P J; Sridhara, R et al. (1993) Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 82:1288-99
Ross, D D; Cuddy, D P; Cohen, N et al. (1992) Mechanistic implications of alterations in HL-60 cell nascent DNA after exposure to 1-beta-D-arabinofuranosylcytosine. Cancer Chemother Pharmacol 31:61-70
Gervasoni Jr, J E; Fields, S Z; Krishna, S et al. (1991) Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res 51:4955-63
de Valeriola, D L; Ross, D D; Forrest, A et al. (1991) Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs. Cancer Chemother Pharmacol 29:133-40

Showing the most recent 10 out of 21 publications